At-home self-injection therapy -- breakthrough convenience and efficacy. Indomo operates in Biotech; this dossier captures the Series B2 we participated in.
Two Tranche Series B; Total $22M round that will end on a $75M post valuation. $53M Pre-Money and $75M post-money. B-1 Price $0.11475 per share B-2 Price $0.15680 per share SH committed $206,869, via StoryHouse Fund II, at a $75M valuation, in a $7M round, alongside Foresite Capital, Polaris, Atomic.
RAW NOTES: • He is at about $400K-425K • Gary at Polaris was supportive of making this happen in general and secondary if necessary • Polaris/Rick could guarantee us access at B-2 to split the difference on the $75K-100K; changes average share price cost from 3%-6% (not a big deal) • Told Rick to keep us posted, that we would like as clos…
Source: Meeting Notes recgPUXJAcumBdwKP
RAW NOTES: • Spoke with Goodwin • Thinks that there is $433 available; asked if we would be okay with that amount. I pushed and said $500K was important, but if necessary $433K might be ok but would need to discuss with Josh/Matt. Rick shared other options for getting us to $500K (secondaries, waiting on Gaingels/Josh Jones check-size). • Confi…
Source: Meeting Notes rec5NwpaC6oZTevS5
RAW NOTES: 22M round led by Foresight 75M post Tranched round; $35M pre-money on a $15M tranche for B-1; B-2 is a $68M pre-money based positive interim data from Phase 2 which will be the trigger for the tranche (this will be end of Q1 2026) Foresite will do 12 of 22 Remaining 10M split between insiders Steven Peterson and Hyung Chung; Jim has als…
Source: Meeting Notes recWpBrp6YLTIiUr9